{"ticker": {"uuid": "6e8cdb5b-8663-41f7-9494-52144fcbd685", "symbol": "ABEO", "name": "Abeona Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Precision Trading with Abeona Therapeutics Inc. (ABEO) Risk Zones", "summary": "This article analyzes Abeona Therapeutics Inc. (ABEO) using AI models to provide trading strategies based on different risk profiles and holding periods. It identifies strong near and mid-term sentiment but a weak long-term outlook for ABEO, with no resistance levels identified a", "url": "https://news.stocktradersdaily.com/news_release/139/Precision_Trading_with_Abeona_Therapeutics_Inc._ABEO_Risk_Zones_071326022401_1783923841.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T02:41:30", "published_display": "13 Jul 2026 02:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (NASDAQ: ABEO) shifts 760,870 warrants to SILV Fund", "summary": "Abeona Therapeutics (NASDAQ: ABEO) has filed a prospectus supplement to update a previous resale registration, indicating the assignment of 760,870 Common Warrants from Point72 Associates, LLC to SILV Fund, Ltd. This update does not change the total number of registered shares fo", "url": "https://www.stocktitan.net/sec-filings/ABEO/424b3-abeona-therapeutics-inc-prospectus-filed-pursuant-to-rule-424-b-8098e7a6d331.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:40:25", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related stock sale by Abeona (ABEO) CEO leaves 1.31M shares", "summary": "Abeona Therapeutics Inc. CEO Vishwas Seshadri sold 67,971 shares of common stock at a weighted average price of $6.9637 per share to cover tax obligations from vesting restricted stock awards. Following this transaction, Seshadri still holds 1,306,108 shares of ABEO. The sale was", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-6ddf162f7cd6.html", "source_name": "Stock Titan", "published_at": "2026-07-10T12:09:21", "published_display": "10 Jul 2026 12:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics CCO Vasanthavada Madhav sells $87,784 in stock", "summary": "Vasanthavada Madhav, CCO of Abeona Therapeutics (NASDAQ:ABEO), sold 12,606 shares totaling $87,784 on July 9, 2026. This sale helps cover tax obligations from stock awards, leaving Madhav with 290,623 shares. The company's stock has seen a significant 37% gain over the past six m", "url": "https://www.investing.com/news/insider-trading-news/abeona-therapeutics-cco-vasanthavada-madhav-sells-87784-in-stock-93CH-4785166", "source_name": "Investing.com", "published_at": "2026-07-10T11:39:34", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona (ABEO) CFO sells 24,880 shares to cover taxes on vested stock", "summary": "Abeona Therapeutics Inc.'s Chief Financial Officer, Joseph Walter Vazzano, sold 24,880 shares of common stock at a weighted average price of $6.9637 per share to cover tax obligations from vested restricted stock awards. Following this transaction, Vazzano directly holds 493,557 ", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-c7159522f798.html", "source_name": "Stock Titan", "published_at": "2026-07-10T11:39:34", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (ABEO) CCO sells 12,606 shares, retains 290,623", "summary": "Abeona Therapeutics' Chief Commercial Officer, Madhav Vasanthavada, sold 12,606 shares of common stock at a weighted average price of $6.9637 per share. This open-market transaction represents a small portion of his holdings, as he retains 290,623 shares after the sale. The sale ", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-6d32ae8012e6.html", "source_name": "Stock Titan", "published_at": "2026-07-10T11:39:34", "published_display": "10 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics CEO Seshadri Vishwas sells $473k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc3RsY0J0TFowOTlDWFRkcERQTkZCMlZSdGl6VDQ4N1hEQkVUR2U3V2VQVFNUNVEwME40aDNKbUkwaWRJTDQ4cWJveXlwVVU1eXdlNEJBRHhRMF9PWHBkTDVQQ2syT1FIQmN5SlBVZ0lQTUF2OXNScmhzaG85MTh5dHFNMUFlWV9aYkNzanVETEJyZm1pTURnMWNBbHBSRE1UV3V3eEx1ME1qeFlPVk1VTENaM3pxcUZyeDczdzU5LWVGbEE?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T23:43:00+00:00", "published_display": "09 Jul 2026 23:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brendan O\u2019Malley sells $83,912 in Abeona Therapeutics stock", "summary": "Brendan M. O\u2019Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics (NASDAQ:ABEO), sold 12,050 shares totaling $83,912 to cover tax obligations from restricted stock awards. Following this transaction, O'Malley still holds 427,953 shares. The company recentl", "url": "https://www.investing.com/news/insider-trading-news/brendan-omalley-sells-83912-in-abeona-therapeutics-stock-93CH-4785169", "source_name": "Investing.com", "published_at": "2026-07-10T00:39:32", "published_display": "10 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Abeona Therapeutics Inc For: 9 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Abeona Therapeutics Inc. for July 9th. Form 4 filings are regulatory documents that disclose changes in stock ownership by company insiders. The brief news item includes the company's stock symbol (ABEO) and its perfo", "url": "https://ng.investing.com/news/stock-market-news/form-4-abeona-therapeutics-inc-for-9-july-93CH-2594101", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T00:26:00", "published_display": "10 Jul 2026 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics CFO Vazzano sells $173,256 in common stock", "summary": "Abeona Therapeutics CFO Joseph Walter Vazzano sold 24,880 shares of the company's common stock for a total of $173,256, at an average price of $6.9637 per share. This sale was conducted to cover tax obligations from vested restricted stock awards. Following the transaction, Vazza", "url": "https://www.investing.com/news/insider-trading-news/abeona-therapeutics-cfo-vazzano-sells-173256-in-common-stock-93CH-4785172", "source_name": "Investing.com", "published_at": "2026-07-09T23:39:34", "published_display": "09 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (ABEO) SVP sells shares to cover tax obligations", "summary": "Brendan M. O'Malley, SVP and Chief Legal Officer of Abeona Therapeutics (ABEO), sold 12,050 shares of common stock at a weighted average price of $6.9637 per share to cover tax obligations from vested restricted stock awards. Following the sale, O'Malley retains 427,953 shares in", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-3f2ada1a2cba.html", "source_name": "Stock Titan", "published_at": "2026-07-09T23:39:34", "published_display": "09 Jul 2026 23:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ABEONA THERAPEUTICS INC. For: 9 July By Investing.com", "summary": "This article announces the filing of Form 144 for ABEONA THERAPEUTICS INC. on July 9. The report is from Investing.com and was published in the Stock Market section. The form filing indicates potential insider transactions or sales of restricted securities.", "url": "https://ca.investing.com/news/stock-market-news/form-144-abeona-therapeutics-inc-for-9-july-93CH-4728054", "source_name": "Investing.com Canada", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO (NASDAQ) Form 144 shows 141,333 restricted shares planned for sale", "summary": "ABEO (Abeona Therapeutics Inc.) filed a Form 144 notice indicating a planned sale of 141,333 Restricted Stock Awards on July 8, 2026. The filing also reports prior sales by Vishwas Seshadri, totaling 56,344 shares in early June 2026, with recorded dollar values. This routine regu", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-9ab63605821f.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider share sales and RSAs reported by ABEO (NASDAQ: ABEO)", "summary": "ABEO (NASDAQ: ABEO) reported insider transactions via a Form 144 disclosure, indicating sales of Common Stock by Madhav Vasanthavada across May and June 2026. The filing also detailed an equity compensation entry of 28,519 Restricted Stock Awards dated July 8, 2026, and stated 56", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-fcf982dcd995.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO (NASDAQ: ABEO) director reports proposed stock sales in Form 144", "summary": "A director of ABEO (NASDAQ: ABEO) has filed a Form 144, disclosing proposed sales of common stock. The filing details a restricted stock award of 51,733 shares on July 8, 2026, and previous proposed sales of 10,271 shares on June 8, 2026, and 39,067 shares on June 9, 2026, with a", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-541c3d28ab4b.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO (Nasdaq: ABEO) files Form 144: 34,230 restricted shares; insider sales noted", "summary": "Abeona Therapeutics Inc. (ABEO) has filed a Form 144, indicating proposed sales of common stock and recent restricted stock awards. The filing specifies 34,230 restricted shares dated July 8, 2026, and notes insider sales by Brendan O'Malley of 4,826 shares on June 8, 2026, and 6", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-f27fc920d312.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO (NASDAQ: ABEO) Rule 144 sale notice \u2014 18,160 shares", "summary": "Abeona Therapeutics Inc. (NASDAQ: ABEO) filed a Rule 144 notice, reporting a sale of 18,160 shares of common stock on June 15, 2026, for total proceeds of $103,695.00. The shares sold trace back to an equity compensation grant on May 20, 2020. The company's outstanding common sto", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-8d0b18c9601f.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:40:41", "published_display": "06 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Abeona Therapeutics Inc. \u2013 NASDAQ:ABEO", "summary": "This article provides a financial overview of Abeona Therapeutics Inc. (NASDAQ: ABEO), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or data-point article from TradingView, offering financial metrics for the company. The content includes navig", "url": "https://www.tradingview.com/symbols/NASDAQ-ABEO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T22:13:02", "published_display": "04 Jul 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (ABEO) director Alland Leila sells 11,000 shares", "summary": "Abeona Therapeutics director Alland Leila reported an open-market sale of 11,000 shares of company common stock at a weighted average price of $5.917 per share. The sale occurred on June 30, 2026, through multiple transactions. Following this sale, Leila directly holds 162,614 sh", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-52f9a80b6254.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:19", "published_display": "02 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO - Abeona Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial statistics for Abeona Therapeutics Inc. (ABEO). It includes details on market performance, key financial ratios, insider and institutional ownership, analyst ratings, and various stock performance metrics.", "url": "https://finviz.com/stock?t=ABEO&ty=lf&ta=0&p=d&page=3", "source_name": "Finviz", "published_at": "2026-07-02T12:09:46", "published_display": "02 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to ABEO Trends in Macro Strategies", "summary": "Abeona Therapeutics Inc. (NASDAQ: ABEO) is showing strong near and mid-term sentiment but a weak long-term outlook, with no clear price positioning signal identified. Quantitative AI models have generated distinct trading strategies, including position, momentum breakout, and ris", "url": "https://news.stocktradersdaily.com/news_release/149/Technical_Reactions_to_ABEO_Trends_in_Macro_Strategies_070226011602_1782969362.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T01:16:00", "published_display": "02 Jul 2026 01:16", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics\u00ae Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Abeona Therapeutics Inc. announced new equity awards granted to five non-executive employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These restricted stock awards, totaling up to 9,000 shares, will vest over three years. Abeona Therapeut", "url": "https://finance.yahoo.com/healthcare/articles/abeona-therapeutics-announces-employee-inducement-113000945.html", "source_name": "Market source", "published_at": "2026-07-01T21:39:33", "published_display": "01 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona gives 5 new hires restricted stock worth 9,000 shares", "summary": "Abeona Therapeutics (Nasdaq: ABEO) has granted equity awards to five new non-executive employees, totaling up to 9,000 restricted shares. These awards serve as a material inducement for employment and will vest in three equal annual installments over three years, contingent on co", "url": "https://www.stocktitan.net/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-b8h3ma1hgdtg.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:40:19", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Abeona Therapeutics Inc. \u2013 NASDAQ:ABEO", "summary": "This article displays the enterprise value to revenue forward for Abeona Therapeutics Inc. (NASDAQ: ABEO). It provides financial data and is presented on the TradingView platform, an interface for market analysis.", "url": "https://www.tradingview.com/symbols/NASDAQ-ABEO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:16", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Abeona Therapeutics, Inc. \u2013 HAM:PCJ", "summary": "This article provides financial information for Abeona Therapeutics, Inc. (PCJ) on the Hamburg Stock Exchange, specifically focusing on its forward price-to-sales ratio. It appears to be a basic financial data display from TradingView, offering an overview of the company's financ", "url": "https://www.tradingview.com/symbols/HAM-PCJ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:16", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Abeona Therapeutics Inc. \u2013 NASDAQ:ABEO", "summary": "The article focuses on the \"Enterprise value to EBITDA forward\" metric for Abeona Therapeutics Inc. (NASDAQ: ABEO). It appears to be a financial data page from TradingView, providing an overview of this specific financial ratio for the company's stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-ABEO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:22", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Abeona Therapeutics, Inc. \u2013 HAM:PCJ", "summary": "This article provides the \"Price to earnings forward\" metric for Abeona Therapeutics, Inc. (HAM:PCJ) on the Hamburg Stock Exchange. The data is presented within a TradingView context, indicating a financial overview for the pharmaceutical company. The market was closed at the tim", "url": "https://www.tradingview.com/symbols/HAM-PCJ/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:41:57", "published_display": "25 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona (NASDAQ: ABEO) director Michael Amoroso steps down from board", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQTUo5SjNLZjB3eDdveHJIQmh3dmdSaHRBZ0J3WjF6YXUzTmtRRE4wTXlDY2VqTHdLVXFpaWRvSEQ3QlFlZ1BLMGNDT0kyUjFfdGltYXA3Y0NMUkVUWHBualNNTkR3TjNDeTlMbGFfTnRvX0JWOGVwVHJVcDluYl9nWGlYSWtEMDdXMXU4aHNaRE9USTJZb1AzQlRRVkE4UkFfMnFIMkx5dlhkQ1lEOHV1Rkhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics CFO Joseph Vazzano sells $265,242 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQY25JN3NLd3BmaE1rcUJxOTRGU04yMEZMbUVhSEJjYW5Wd1ZYbWw4eGRxbk5MSE4td3BwOHU2YU9POVV3eUpMa0RPQU8wTkVyRFd0ODNGcjlKV3ppSTJBeldIVEwtQXVQN0hmUVZSc2otS3NxRjNtNFZjSzJfQWt0MXAxS3JVNUJDSWxuQzJuUkExYXNzZTZzT0hFakFJNTR0cDQ0ZWdCV2x2LU1QQTIyWVh4TXdZTXhnaWMzOHFvb1V3V28?oc=5", "source_name": "Investing.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Abeona Therapeutics beats Q1 2026 forecasts, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTWZzWHkxdlk3MG5KVWdnTXBWWmhhNF9NcU1rZEpYRGluSWxKVjNFMzduOTBzM1k2eFphVlRDQnEtRWhFNGxQX29JeUN4LUpFRkpTNlZFWkFLVUxuaEFjNEU2bENnSE9KaXpSLTB0NjJSOGV0Tk1NVGQ5Rm8xQ1NsVDlMNm1ZNTJMeTlNS1FJd1BHU2NESUk0QWxocDVmUkR0YmNMQlFpNzNQRHpJa25XVFJ2NlZCS0lUeXAxUkNFWW5pamZVLVVrQUs3SWVSdUgy?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abeona Therapeutics Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZzlvVFZHWDZEX1ZvdDBIQ0dOeFk5Yl9uYVg1LUVraHFpdUM1eEFqUnhyT1Y4c0s0T0Z1QkpHbWhNR1loTC1oTHJFNE1lVks3RTdTaUh1QTl4TUFRdHJDMjNVbXdZLWJsWk9lVkU3aXhQQUdubm9GcGl5eGpxMFEyX1VjT3Q2Umo4ZXFKYtIBjAFBVV95cUxQZzlvVFZHWDZEX1ZvdDBIQ0dOeFk5Yl9uYVg1LUVraHFpdUM1eEFqUnhyT1Y4c0s0T0Z1QkpHbWhNR1loTC1oTHJFNE1lVks3RTdTaUh1QTl4TUFRdHJDMjNVbXdZLWJsWk9lVkU3aXhQQUdubm9GcGl5eGpxMFEyX1VjT3Q2Umo4ZXFKYg?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics\u00ae Reports First Quarter 2026 Results and Provides Pipeline Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQTlNjck92V2RXdGV6ZUJMbDh1WHBldXFxcXh2WFVEaEo5LUZlQkh1b3R0a3l2bUNnX3RncDNiT0xwcHBIQ2tHX0tWQjZ4TVh6Q29UZmhmNm56VWgwU0JWV1JVUnliM3hSTTV5Vk8ySUpqNjBIejBlUnhFTkV0MHpFcFNsNTZfR2lGbEpfU0E4UnlzVGg1Nk9HRTlpaE9UYWQyUlEyS1RyMldxN1ZqRXJRTWlqM2RFNGtiVThWMGg3bVZLMFk2dm1YU1luOS0zb3B0OHZpUlVLU19iWEprN0pPb2ZkemlTOXEyeVVR?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQbXBwcS1iMTJsVmVKMzBFdFZycXBLVlp3a2UzU013V0t1RjBhb2R2aHYtM2hUS2ZLRDB5QnBaQXZPRUVxNHkwVmFHa095bnN1d28zQmY3OElHbDRWNERDcGNuSnpNcU9YMlhmeEFzLVhnTVNhUDdJOE1GNWstT0pEc3ZsSzl3OXpRclhIYVh0Sm5vODNQR1N4SU8yOUZ1cS1DZWhrb2JjMHh3T1cz?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOSERMSmJMd1JOZXZTaUFreWd2anBUa0c0XzVNdDNGS05FM0I1Qy16SzRvTDRSbmlqQ3MteUU2bFlRT0o5aEN4TFVrRTFtclNPWWlxS2VCTklhNFVwczBRcllsaDdtUHdCQk9hY3k5bmo3S2l3STNQTm1QSU5VZDY2Vm1kZ0xQbmMxQV9QMVQzdzREMDZOY0lfUVB2RzF0NmEtVjRtUEZWVQ?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abeona Therapeutics (ABEO) One Off US$152.4m Gain Tests Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEONA THERAPEUTICS ($ABEO) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQbTgtMTNSeEtqcnJkVnlSeHFoZk1ZcWp2Y0tST0gwTkdjUEUwLXZ5Y0NpTXZhcVpUSnJJbnpDeDNBbm80dHN2NDdkQVBONjFBUjhkX1VYd05aNkZMd2JYd0FTX0g1elBsbFFrNW1kWTR2X1lhNlpvTzFmOFNnODM3dThSTElfZkxHNlRFR2hkRW9vTzlFTDdr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (ABEO): Assessing Value After J-Code Milestone for ZEVASKYN Approval", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Loss-Making Abeona Therapeutics Inc. (NASDAQ:ABEO) Set To Breakeven", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-18T07:00:00+00:00", "published_display": "18 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Precision Trading with Abeona Therapeutics Inc. (ABEO) Risk Zones", "summary": "This article analyzes Abeona Therapeutics Inc. (ABEO) using AI models to provide trading strategies based on different risk profiles and holding periods. It identifies strong near and mid-term sentiment but a weak long-term outlook for ABEO, with no resistance levels identified a", "url": "https://news.stocktradersdaily.com/news_release/139/Precision_Trading_with_Abeona_Therapeutics_Inc._ABEO_Risk_Zones_071326022401_1783923841.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T02:41:30", "published_display": "13 Jul 2026 02:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (NASDAQ: ABEO) shifts 760,870 warrants to SILV Fund", "summary": "Abeona Therapeutics (NASDAQ: ABEO) has filed a prospectus supplement to update a previous resale registration, indicating the assignment of 760,870 Common Warrants from Point72 Associates, LLC to SILV Fund, Ltd. This update does not change the total number of registered shares fo", "url": "https://www.stocktitan.net/sec-filings/ABEO/424b3-abeona-therapeutics-inc-prospectus-filed-pursuant-to-rule-424-b-8098e7a6d331.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:40:25", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related stock sale by Abeona (ABEO) CEO leaves 1.31M shares", "summary": "Abeona Therapeutics Inc. CEO Vishwas Seshadri sold 67,971 shares of common stock at a weighted average price of $6.9637 per share to cover tax obligations from vesting restricted stock awards. Following this transaction, Seshadri still holds 1,306,108 shares of ABEO. The sale was", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-6ddf162f7cd6.html", "source_name": "Stock Titan", "published_at": "2026-07-10T12:09:21", "published_display": "10 Jul 2026 12:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics CCO Vasanthavada Madhav sells $87,784 in stock", "summary": "Vasanthavada Madhav, CCO of Abeona Therapeutics (NASDAQ:ABEO), sold 12,606 shares totaling $87,784 on July 9, 2026. This sale helps cover tax obligations from stock awards, leaving Madhav with 290,623 shares. The company's stock has seen a significant 37% gain over the past six m", "url": "https://www.investing.com/news/insider-trading-news/abeona-therapeutics-cco-vasanthavada-madhav-sells-87784-in-stock-93CH-4785166", "source_name": "Investing.com", "published_at": "2026-07-10T11:39:34", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona (ABEO) CFO sells 24,880 shares to cover taxes on vested stock", "summary": "Abeona Therapeutics Inc.'s Chief Financial Officer, Joseph Walter Vazzano, sold 24,880 shares of common stock at a weighted average price of $6.9637 per share to cover tax obligations from vested restricted stock awards. Following this transaction, Vazzano directly holds 493,557 ", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-c7159522f798.html", "source_name": "Stock Titan", "published_at": "2026-07-10T11:39:34", "published_display": "10 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (ABEO) CCO sells 12,606 shares, retains 290,623", "summary": "Abeona Therapeutics' Chief Commercial Officer, Madhav Vasanthavada, sold 12,606 shares of common stock at a weighted average price of $6.9637 per share. This open-market transaction represents a small portion of his holdings, as he retains 290,623 shares after the sale. The sale ", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-6d32ae8012e6.html", "source_name": "Stock Titan", "published_at": "2026-07-10T11:39:34", "published_display": "10 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics CEO Seshadri Vishwas sells $473k in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc3RsY0J0TFowOTlDWFRkcERQTkZCMlZSdGl6VDQ4N1hEQkVUR2U3V2VQVFNUNVEwME40aDNKbUkwaWRJTDQ4cWJveXlwVVU1eXdlNEJBRHhRMF9PWHBkTDVQQ2syT1FIQmN5SlBVZ0lQTUF2OXNScmhzaG85MTh5dHFNMUFlWV9aYkNzanVETEJyZm1pTURnMWNBbHBSRE1UV3V3eEx1ME1qeFlPVk1VTENaM3pxcUZyeDczdzU5LWVGbEE?oc=5", "source_name": "Investing.com", "published_at": "2026-07-09T23:43:00+00:00", "published_display": "09 Jul 2026 23:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brendan O\u2019Malley sells $83,912 in Abeona Therapeutics stock", "summary": "Brendan M. O\u2019Malley, Senior Vice President and Chief Legal Officer of Abeona Therapeutics (NASDAQ:ABEO), sold 12,050 shares totaling $83,912 to cover tax obligations from restricted stock awards. Following this transaction, O'Malley still holds 427,953 shares. The company recentl", "url": "https://www.investing.com/news/insider-trading-news/brendan-omalley-sells-83912-in-abeona-therapeutics-stock-93CH-4785169", "source_name": "Investing.com", "published_at": "2026-07-10T00:39:32", "published_display": "10 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Abeona Therapeutics Inc For: 9 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Abeona Therapeutics Inc. for July 9th. Form 4 filings are regulatory documents that disclose changes in stock ownership by company insiders. The brief news item includes the company's stock symbol (ABEO) and its perfo", "url": "https://ng.investing.com/news/stock-market-news/form-4-abeona-therapeutics-inc-for-9-july-93CH-2594101", "source_name": "Investing.com Nigeria", "published_at": "2026-07-10T00:26:00", "published_display": "10 Jul 2026 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics CFO Vazzano sells $173,256 in common stock", "summary": "Abeona Therapeutics CFO Joseph Walter Vazzano sold 24,880 shares of the company's common stock for a total of $173,256, at an average price of $6.9637 per share. This sale was conducted to cover tax obligations from vested restricted stock awards. Following the transaction, Vazza", "url": "https://www.investing.com/news/insider-trading-news/abeona-therapeutics-cfo-vazzano-sells-173256-in-common-stock-93CH-4785172", "source_name": "Investing.com", "published_at": "2026-07-09T23:39:34", "published_display": "09 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (ABEO) SVP sells shares to cover tax obligations", "summary": "Brendan M. O'Malley, SVP and Chief Legal Officer of Abeona Therapeutics (ABEO), sold 12,050 shares of common stock at a weighted average price of $6.9637 per share to cover tax obligations from vested restricted stock awards. Following the sale, O'Malley retains 427,953 shares in", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-3f2ada1a2cba.html", "source_name": "Stock Titan", "published_at": "2026-07-09T23:39:34", "published_display": "09 Jul 2026 23:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 ABEONA THERAPEUTICS INC. For: 9 July By Investing.com", "summary": "This article announces the filing of Form 144 for ABEONA THERAPEUTICS INC. on July 9. The report is from Investing.com and was published in the Stock Market section. The form filing indicates potential insider transactions or sales of restricted securities.", "url": "https://ca.investing.com/news/stock-market-news/form-144-abeona-therapeutics-inc-for-9-july-93CH-4728054", "source_name": "Investing.com Canada", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO (NASDAQ) Form 144 shows 141,333 restricted shares planned for sale", "summary": "ABEO (Abeona Therapeutics Inc.) filed a Form 144 notice indicating a planned sale of 141,333 Restricted Stock Awards on July 8, 2026. The filing also reports prior sales by Vishwas Seshadri, totaling 56,344 shares in early June 2026, with recorded dollar values. This routine regu", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-9ab63605821f.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider share sales and RSAs reported by ABEO (NASDAQ: ABEO)", "summary": "ABEO (NASDAQ: ABEO) reported insider transactions via a Form 144 disclosure, indicating sales of Common Stock by Madhav Vasanthavada across May and June 2026. The filing also detailed an equity compensation entry of 28,519 Restricted Stock Awards dated July 8, 2026, and stated 56", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-fcf982dcd995.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO (NASDAQ: ABEO) director reports proposed stock sales in Form 144", "summary": "A director of ABEO (NASDAQ: ABEO) has filed a Form 144, disclosing proposed sales of common stock. The filing details a restricted stock award of 51,733 shares on July 8, 2026, and previous proposed sales of 10,271 shares on June 8, 2026, and 39,067 shares on June 9, 2026, with a", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-541c3d28ab4b.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO (Nasdaq: ABEO) files Form 144: 34,230 restricted shares; insider sales noted", "summary": "Abeona Therapeutics Inc. (ABEO) has filed a Form 144, indicating proposed sales of common stock and recent restricted stock awards. The filing specifies 34,230 restricted shares dated July 8, 2026, and notes insider sales by Brendan O'Malley of 4,826 shares on June 8, 2026, and 6", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-f27fc920d312.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:14:50", "published_display": "09 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO (NASDAQ: ABEO) Rule 144 sale notice \u2014 18,160 shares", "summary": "Abeona Therapeutics Inc. (NASDAQ: ABEO) filed a Rule 144 notice, reporting a sale of 18,160 shares of common stock on June 15, 2026, for total proceeds of $103,695.00. The shares sold trace back to an equity compensation grant on May 20, 2020. The company's outstanding common sto", "url": "https://www.stocktitan.net/sec-filings/ABEO/144-abeona-therapeutics-inc-sec-filing-8d0b18c9601f.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:40:41", "published_display": "06 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Abeona Therapeutics Inc. \u2013 NASDAQ:ABEO", "summary": "This article provides a financial overview of Abeona Therapeutics Inc. (NASDAQ: ABEO), specifically focusing on its forward price-to-sales ratio. It appears to be a stub or data-point article from TradingView, offering financial metrics for the company. The content includes navig", "url": "https://www.tradingview.com/symbols/NASDAQ-ABEO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T22:13:02", "published_display": "04 Jul 2026 22:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (ABEO) director Alland Leila sells 11,000 shares", "summary": "Abeona Therapeutics director Alland Leila reported an open-market sale of 11,000 shares of company common stock at a weighted average price of $5.917 per share. The sale occurred on June 30, 2026, through multiple transactions. Following this sale, Leila directly holds 162,614 sh", "url": "https://www.stocktitan.net/sec-filings/ABEO/form-4-abeona-therapeutics-inc-insider-trading-activity-52f9a80b6254.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:19", "published_display": "02 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEO - Abeona Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial statistics for Abeona Therapeutics Inc. (ABEO). It includes details on market performance, key financial ratios, insider and institutional ownership, analyst ratings, and various stock performance metrics.", "url": "https://finviz.com/stock?t=ABEO&ty=lf&ta=0&p=d&page=3", "source_name": "Finviz", "published_at": "2026-07-02T12:09:46", "published_display": "02 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Reactions to ABEO Trends in Macro Strategies", "summary": "Abeona Therapeutics Inc. (NASDAQ: ABEO) is showing strong near and mid-term sentiment but a weak long-term outlook, with no clear price positioning signal identified. Quantitative AI models have generated distinct trading strategies, including position, momentum breakout, and ris", "url": "https://news.stocktradersdaily.com/news_release/149/Technical_Reactions_to_ABEO_Trends_in_Macro_Strategies_070226011602_1782969362.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T01:16:00", "published_display": "02 Jul 2026 01:16", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics\u00ae Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Abeona Therapeutics Inc. announced new equity awards granted to five non-executive employees as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These restricted stock awards, totaling up to 9,000 shares, will vest over three years. Abeona Therapeut", "url": "https://finance.yahoo.com/healthcare/articles/abeona-therapeutics-announces-employee-inducement-113000945.html", "source_name": "Market source", "published_at": "2026-07-01T21:39:33", "published_display": "01 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona gives 5 new hires restricted stock worth 9,000 shares", "summary": "Abeona Therapeutics (Nasdaq: ABEO) has granted equity awards to five new non-executive employees, totaling up to 9,000 restricted shares. These awards serve as a material inducement for employment and will vest in three equal annual installments over three years, contingent on co", "url": "https://www.stocktitan.net/news/ABEO/abeona-therapeutics-announces-new-employee-inducement-grants-under-b8h3ma1hgdtg.html", "source_name": "Stock Titan", "published_at": "2026-07-01T11:40:19", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Abeona Therapeutics Inc. \u2013 NASDAQ:ABEO", "summary": "This article displays the enterprise value to revenue forward for Abeona Therapeutics Inc. (NASDAQ: ABEO). It provides financial data and is presented on the TradingView platform, an interface for market analysis.", "url": "https://www.tradingview.com/symbols/NASDAQ-ABEO/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:16", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Abeona Therapeutics, Inc. \u2013 HAM:PCJ", "summary": "This article provides financial information for Abeona Therapeutics, Inc. (PCJ) on the Hamburg Stock Exchange, specifically focusing on its forward price-to-sales ratio. It appears to be a basic financial data display from TradingView, offering an overview of the company's financ", "url": "https://www.tradingview.com/symbols/HAM-PCJ/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:16", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Abeona Therapeutics Inc. \u2013 NASDAQ:ABEO", "summary": "The article focuses on the \"Enterprise value to EBITDA forward\" metric for Abeona Therapeutics Inc. (NASDAQ: ABEO). It appears to be a financial data page from TradingView, providing an overview of this specific financial ratio for the company's stock.", "url": "https://www.tradingview.com/symbols/NASDAQ-ABEO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T04:10:22", "published_display": "26 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Abeona Therapeutics, Inc. \u2013 HAM:PCJ", "summary": "This article provides the \"Price to earnings forward\" metric for Abeona Therapeutics, Inc. (HAM:PCJ) on the Hamburg Stock Exchange. The data is presented within a TradingView context, indicating a financial overview for the pharmaceutical company. The market was closed at the tim", "url": "https://www.tradingview.com/symbols/HAM-PCJ/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T13:41:57", "published_display": "25 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona (NASDAQ: ABEO) director Michael Amoroso steps down from board", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQTUo5SjNLZjB3eDdveHJIQmh3dmdSaHRBZ0J3WjF6YXUzTmtRRE4wTXlDY2VqTHdLVXFpaWRvSEQ3QlFlZ1BLMGNDT0kyUjFfdGltYXA3Y0NMUkVUWHBualNNTkR3TjNDeTlMbGFfTnRvX0JWOGVwVHJVcDluYl9nWGlYSWtEMDdXMXU4aHNaRE9USTJZb1AzQlRRVkE4UkFfMnFIMkx5dlhkQ1lEOHV1Rkhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics CFO Joseph Vazzano sells $265,242 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQY25JN3NLd3BmaE1rcUJxOTRGU04yMEZMbUVhSEJjYW5Wd1ZYbWw4eGRxbk5MSE4td3BwOHU2YU9POVV3eUpMa0RPQU8wTkVyRFd0ODNGcjlKV3ppSTJBeldIVEwtQXVQN0hmUVZSc2otS3NxRjNtNFZjSzJfQWt0MXAxS3JVNUJDSWxuQzJuUkExYXNzZTZzT0hFakFJNTR0cDQ0ZWdCV2x2LU1QQTIyWVh4TXdZTXhnaWMzOHFvb1V3V28?oc=5", "source_name": "Investing.com", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Abeona Therapeutics beats Q1 2026 forecasts, stock dips", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTWZzWHkxdlk3MG5KVWdnTXBWWmhhNF9NcU1rZEpYRGluSWxKVjNFMzduOTBzM1k2eFphVlRDQnEtRWhFNGxQX29JeUN4LUpFRkpTNlZFWkFLVUxuaEFjNEU2bENnSE9KaXpSLTB0NjJSOGV0Tk1NVGQ5Rm8xQ1NsVDlMNm1ZNTJMeTlNS1FJd1BHU2NESUk0QWxocDVmUkR0YmNMQlFpNzNQRHpJa25XVFJ2NlZCS0lUeXAxUkNFWW5pamZVLVVrQUs3SWVSdUgy?oc=5", "source_name": "Investing.com", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics Releases Q1 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZzlvVFZHWDZEX1ZvdDBIQ0dOeFk5Yl9uYVg1LUVraHFpdUM1eEFqUnhyT1Y4c0s0T0Z1QkpHbWhNR1loTC1oTHJFNE1lVks3RTdTaUh1QTl4TUFRdHJDMjNVbXdZLWJsWk9lVkU3aXhQQUdubm9GcGl5eGpxMFEyX1VjT3Q2Umo4ZXFKYtIBjAFBVV95cUxQZzlvVFZHWDZEX1ZvdDBIQ0dOeFk5Yl9uYVg1LUVraHFpdUM1eEFqUnhyT1Y4c0s0T0Z1QkpHbWhNR1loTC1oTHJFNE1lVks3RTdTaUh1QTl4TUFRdHJDMjNVbXdZLWJsWk9lVkU3aXhQQUdubm9GcGl5eGpxMFEyX1VjT3Q2Umo4ZXFKYg?oc=5", "source_name": "AlphaStreet", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics\u00ae Reports First Quarter 2026 Results and Provides Pipeline Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQTlNjck92V2RXdGV6ZUJMbDh1WHBldXFxcXh2WFVEaEo5LUZlQkh1b3R0a3l2bUNnX3RncDNiT0xwcHBIQ2tHX0tWQjZ4TVh6Q29UZmhmNm56VWgwU0JWV1JVUnliM3hSTTV5Vk8ySUpqNjBIejBlUnhFTkV0MHpFcFNsNTZfR2lGbEpfU0E4UnlzVGg1Nk9HRTlpaE9UYWQyUlEyS1RyMldxN1ZqRXJRTWlqM2RFNGtiVThWMGg3bVZLMFk2dm1YU1luOS0zb3B0OHZpUlVLU19iWEprN0pPb2ZkemlTOXEyeVVR?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQbXBwcS1iMTJsVmVKMzBFdFZycXBLVlp3a2UzU013V0t1RjBhb2R2aHYtM2hUS2ZLRDB5QnBaQXZPRUVxNHkwVmFHa095bnN1d28zQmY3OElHbDRWNERDcGNuSnpNcU9YMlhmeEFzLVhnTVNhUDdJOE1GNWstT0pEc3ZsSzl3OXpRclhIYVh0Sm5vODNQR1N4SU8yOUZ1cS1DZWhrb2JjMHh3T1cz?oc=5", "source_name": "TradingView", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOSERMSmJMd1JOZXZTaUFreWd2anBUa0c0XzVNdDNGS05FM0I1Qy16SzRvTDRSbmlqQ3MteUU2bFlRT0o5aEN4TFVrRTFtclNPWWlxS2VCTklhNFVwczBRcllsaDdtUHdCQk9hY3k5bmo3S2l3STNQTm1QSU5VZDY2Vm1kZ0xQbmMxQV9QMVQzdzREMDZOY0lfUVB2RzF0NmEtVjRtUEZWVQ?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (ABEO) One Off US$152.4m Gain Tests Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABEONA THERAPEUTICS ($ABEO) Releases Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQbTgtMTNSeEtqcnJkVnlSeHFoZk1ZcWp2Y0tST0gwTkdjUEUwLXZ5Y0NpTXZhcVpUSnJJbnpDeDNBbm80dHN2NDdkQVBONjFBUjhkX1VYd05aNkZMd2JYd0FTX0g1elBsbFFrNW1kWTR2X1lhNlpvTzFmOFNnODM3dThSTElfZkxHNlRFR2hkRW9vTzlFTDdr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abeona Therapeutics (ABEO): Assessing Value After J-Code Milestone for ZEVASKYN Approval", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Loss-Making Abeona Therapeutics Inc. (NASDAQ:ABEO) Set To Breakeven", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-18T07:00:00+00:00", "published_display": "18 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 46, "sentiment_summary": {"positive": 8, "negative": 5, "neutral": 33, "score": 52, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 14.3, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 6.98, "latest_week": "2026-07-10", "one_week_move": 9.1, "four_week_move": 26.2, "twelve_week_move": 26.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.407363, "market_dynamics_buy_signal": false, "relative_strength": 8.531113, "fair_value_gap": 29.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 44.159, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+9.1% over one week, +26.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 7}, {"label": "Investing.com", "count": 6}, {"label": "simplywall.st", "count": 5}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Investing.com Nigeria", "count": 1}, {"label": "Investing.com Canada", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 38}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 15}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "38", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+9.1% over one week, +26.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Precision Trading with Abeona Therapeutics Inc. (ABEO) Risk Zones"}], "updated_at": "2026-07-16T05:28:36.577490+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}